biotech
biotech Articles
In a recent research report, Jefferies is out with its top growth stock calls to kick off June, and we found three that look very attractive now and that also seem to have outsized upside potential.
Published:
Last Updated:
Clearside Biomedical expects to price more than 7 million shares at $7 per share for an initial public offering valued up to nearly $58 million.
Published:
Last Updated:
StemCells just reminded investors and speculators alike just how dangerous it can be to invest in biotech and biohealth companies.
Published:
Last Updated:
AC Immune has filed with the U.S. Securities & Exchange Commission (SEC) to pursue an initial public offering (IPO).
Published:
Last Updated:
The American Society of Clinical Oncology (ASCO) is gearing up for its annual meeting. At this meeting, cancer drug developers will share the results from their most recent drug trials.
Published:
Last Updated:
Here are seven speculative biotech and biohealth players in which analyst calls during the week ending May 27 have given major upside projections.
Published:
Last Updated:
These two biotech companies not only have data that could prove to be huge, but the stocks have been absolutely hammered over the past year, offering the best entry points in some time.
Published:
Last Updated:
Minerva Neurosciences saw its shares make absolutely massive gains on Thursday following the release of positive results from a couple mid-stage clinical trials.
Published:
Last Updated:
Many companies are being discussed as Zika virus winners, but the reality is that many of them are so small or have sketchy histories. This is why we are featuring seven notable companies targeting...
Published:
Last Updated:
Selecta Biosciences has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares saw a handy gain on Wednesday following an analyst upgrade from Janney Montgomery Scott.
Published:
Last Updated:
Cellectar Biosciences watched its shares skyrocket on Wednesday morning following the announcement that it has obtained a patent that covers CLR 1603, a phospholipid ether-paclitaxel.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions and imminent clinical trial results that should be coming up in the June quarter. We have added some color.
Published:
Last Updated:
The May 13 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
Published:
Last Updated:
PDL BioPharma Inc. (NASDAQ: PDLI) has now shown where its next revenue stream will be coming from. The company announced on Tuesday that it has committed to an equity investment in Noden Pharma DAC....
Published:
Last Updated: